z-logo
open-access-imgOpen Access
Management of preterm labor: atosiban or nifedipine?
Author(s) -
Roel de Heus
Publication year - 2010
Publication title -
international journal of women s health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.136
H-Index - 45
ISSN - 1179-1411
DOI - 10.2147/ijwh.s7219
Subject(s) - nifedipine , tocolytic agent , tocolytic , medicine , oxytocin , preterm labour , preterm labor , ritodrine , anesthesia , oxytocin receptor , obstetrics , pregnancy , fetus , gestation , calcium , biology , genetics
Preterm birth is strongly associated with neonatal death and long-term neurological morbidity. The purpose of tocolytic drug administration is to postpone threatening preterm delivery for 48 hours to allow maximal effect of antenatal corticosteroids and maternal transportation to a center with specialized neonatal care facilities. There is uncertainty about the value of atosiban (oxytocin receptor antagonist) and nifedipine (calcium channel blocker) as first-line tocolytic drugs in the management of preterm labor. For nifedipine, concerns have been raised about unproven safety, lack of placebo-controlled trials, and its off-label use. The tocolytic efficacy of atosiban has also been questioned because of a lack of reduction in neonatal morbidity. This review discusses the available evidence, the pros and cons of either drug and aims to provide information to support a balanced choice of first-line tocolytic drug: atosiban or nifedipine?

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom